Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales
Executive Summary
Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors
You may also be interested in...
With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.
Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.